journal article·2018-10-31Open access

Beta carotene-loaded zein nanoparticles to improve the biopharmaceutical attributes and to abolish the toxicity of methotrexate: a preclinical study for breast cancer

Ashay Jain, Gajanand Sharma, Varun Kushwah, Gargi Ghoshal, Atul Jain, Bhupinder Singh, U. S. Shivhare, Sanyog Jain, O. P. Katare

Abstract

Beta carotene (βC) loaded nanoparticles of zein (βC-NPs) were developed using modified phase separation technique. βC-NPs were prepared using different zein concentration and optimized formulation was selected on the basis of micromeritics properties and entrapment efficiency. Further, βC-NPs were evaluated for in vitro release, in vitro cell-survival, cellular localization and apoptosis induced in MCF-7 cells. The combined effect of the βC and its nanoparticulate counterpart with MTX was evaluated thereafter for cytotoxicity and apoptotic activity in MCF-7 cells. In comparison to free βC, the βC-NPs demonstrated noteworthy improvement in various biopharmaceutical attributes viz Cmax (∼2.3-folds), AUCtotal (2.7-folds), t1/2 (∼1.5 folds) and MRT (∼1.5 folds), further indicating the remarkable increment in oral bioavailability of βC after incorporation in zein nanoparticles. The anti-tumour potential of prepared βC-NPs and effects of free βC and βC-NPs were investigated upon anticancer efficacy of methotrexate (MTX) in experimentally induced breast cancer rat model. Protective role of βC on MTX-associated hepatic toxicity in wistar rats was also determined using haematological and histopathological approaches. In a nutshell, zein nanoparticles improved the cellular uptake, cytotoxicity and exhibited enhanced oral biopharmaceutical performance of βC. This combination regimen could also be promising platform to facilitate the therapeutic benefits of anticancer agents.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Phytase and its Applications · Proteins in Food Systems · Pomegranate: compositions and health benefits

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

University Institute of Pharmaceutical Sciences, Panjab University

UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites, Panjab University

Dr. S. S. Bhatnagar University Institute of Chemical Engineering & Technology, Panjab University

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research

References (46)

Show source-provided references
1. American Cancer Society. Cancer Facts & Figures 2017. 2017.
2. 10.2174/138161282166615080315203310.2174/1381612821666150803152033 ↗
3. 10.1080/102841502100003376710.1080/1028415021000033767 ↗
4. 10.1021/jf100082p10.1021/jf100082p ↗
5. 10.1016/j.lungcan.2010.06.00210.1016/j.lungcan.2010.06.002 ↗
6. 10.1016/j.jfca.2006.02.00910.1016/j.jfca.2006.02.009 ↗
7. 10.2217/nnm-2017-001110.2217/nnm-2017-0011 ↗
8. 10.1007/s11947-015-1521-010.1007/s11947-015-1521-0 ↗
9. 10.1208/s12249-017-0806-110.1208/s12249-017-0806-1 ↗
10. 10.1016/j.ijbiomac.2016.01.11710.1016/j.ijbiomac.2016.01.117 ↗
11. 10.1111/j.1750-3841.2009.01457.x10.1111/j.1750-3841.2009.01457.x ↗
12. 10.1016/S1773-2247(09)50007-X10.1016/S1773-2247(09)50007-X ↗
13. 10.1016/j.ijbiomac.2016.08.07110.1016/j.ijbiomac.2016.08.071 ↗
14. 10.1016/j.actbio.2015.06.02710.1016/j.actbio.2015.06.027 ↗
15. 10.1016/j.ejps.2012.09.01210.1016/j.ejps.2012.09.012 ↗
16. 10.1016/j.colsurfb.2015.06.02710.1016/j.colsurfb.2015.06.027 ↗
17. 10.1016/j.jconrel.2010.09.00310.1016/j.jconrel.2010.09.003 ↗
18. 10.1016/j.colsurfb.2014.05.04110.1016/j.colsurfb.2014.05.041 ↗
19. 10.1016/j.foodhyd.2011.11.01310.1016/j.foodhyd.2011.11.013 ↗
20. 10.3109/03639045.2015.110434310.3109/03639045.2015.1104343 ↗
21. 10.1021/ma402561910.1021/ma4025619 ↗
22. 10.1021/ja303229510.1021/ja3032295 ↗
23. 10.1021/am402883910.1021/am4028839 ↗
24. 10.1021/la101688v10.1021/la101688v ↗
25. 10.1002/adma.20140118210.1002/adma.201401182 ↗
26. 10.1016/j.colsurfb.2011.02.02010.1016/j.colsurfb.2011.02.020 ↗
27. 10.1177/096120331142270910.1177/0961203311422709 ↗
28. 10.1016/j.lwt.2011.01.00510.1016/j.lwt.2011.01.005 ↗
29. 10.1021/jf040492p10.1021/jf040492p ↗
30. 10.1016/j.ijpharm.2010.11.02510.1016/j.ijpharm.2010.11.025 ↗
31. Kennedy A Scemama J-L Virag J et al. Cryopreservation using sucralose. United States. 2016.
32. 10.1016/j.colsurfb.2016.01.04810.1016/j.colsurfb.2016.01.048 ↗
33. 10.1016/j.colsurfb.2017.01.05010.1016/j.colsurfb.2017.01.050 ↗
34. 10.1016/j.colsurfb.2016.05.05110.1016/j.colsurfb.2016.05.051 ↗
35. 10.1016/j.ijpharm.2013.01.02910.1016/j.ijpharm.2013.01.029 ↗
36. 10.1021/acs.molpharmaceut.6b0114810.1021/acs.molpharmaceut.6b01148 ↗
37. Huggins C, Fukunishi R. Mammary and peritoneal tumors induced by intraperitoneal administration of 7,12-dimethylbenz[a]anthracene in newborn and adult rats. Cancer Res. 1963;23:785–789.
38. 10.7150/ijbs.5.46610.7150/ijbs.5.466 ↗
39. 10.1016/S0190-9622(03)00803-X10.1016/S0190-9622(03)00803-X ↗
40. 10.2144/98244rr0110.2144/98244rr01 ↗
41. 10.1016/j.ijpharm.2011.09.03910.1016/j.ijpharm.2011.09.039 ↗
42. 10.1021/jf505694e10.1021/jf505694e ↗
43. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
44. 10.1021/mp400303w10.1021/mp400303w ↗
45. 10.1016/j.ijpharm.2011.05.05610.1016/j.ijpharm.2011.05.056 ↗
46. 10.1016/j.fct.2009.04.02110.1016/j.fct.2009.04.021 ↗